Evidence map›Paper›PMID 35876873›Full record

ArticleApplied microbiology and biotechnology2022

Recombinant production and characterization of L-glutaminase (glsA) as a promiscuity therapeutic enzyme.

Shayan Simay, Mostafa Akbarzadeh-Khiavi, Mohammad M Pourseif, Jaleh Barar, Azam Safary, Yadollah Omidi

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Shayan Simay *Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Mostafa Akbarzadeh-Khiavi *Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad M Pourseif *Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Jaleh BararResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Azam SafaryConnective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. azamsafary@yahoo.com.ORCID http://orcid.org/0000-0002-8997-2003
Yadollah OmidiDepartment of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, 33328, USA. yomidi@nova.edu.ORCID http://orcid.org/0000-0003-0067-2475
Tabriz University of Medical Sciences · IRNova Southeastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of the therapeutical impacts of hydrolytic enzymes in different diseases, in particular malignancies, we aimed to produce a recombinant putative L-glutaminase (GLS A

Indexed as

BacillusNeoplasmsAsparaginaseAsparagineGlutaminaseGlutamineHumansMolecular Docking SimulationAsparaginaseAsparagineGlutaminaseGlutamineCloningHalo-thermotolerant BacillusL-glutaminaseMolecular dockingPromiscuous functionRecombinant enzyme

Identifiers

PMID35876873
OpenAlexW4287147371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.